Enzyme replacement therapy for Anderson-Fabry disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 7, 2016, Pages

  El Dib, Regina ^a   Gomaa, Huda ^b   Carvalho, Raíssa Pierri ^a   Camargo, Samira E ^a   Bazan, Rodrigo ^a   Barretti, Pasqual ^a   Barreto, Fellype C ^c,d  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Tanta Chest Hospital   (Egypt)

^c PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; GLOBOTRIAOSYLCERAMIDE; PLACEBO; ALPHA GALACTOSIDASE; CERAMIDE TRIHEXOSIDE; ISOENZYME;

BIOPSY; BRIEF PAIN INVENTORY; BRIEF PAIN INVENTORY PAIN RELATED QUALITY OF LIFE; CEREBROVASCULAR DISEASE; DEATH; DRUG SAFETY; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; HEART DISEASE; HISTOLOGY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MCGILL PAIN QUESTIONNAIRE; META ANALYSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PLASMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SHORT FORM 36; SKIN DISEASE; SYSTEMATIC REVIEW; THERAPY EFFECT; TISSUES; UNSPECIFIED SIDE EFFECT; BLOOD; ENZYMOLOGY; FEMALE; MALE; PAIN MEASUREMENT; PROCEDURES; TIME FACTOR;

ALPHA-GALACTOSIDASE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MALE; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TRIHEXOSYLCERAMIDES;

EID: 84979708513     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006663.pub4     Document Type: Review

References (109)

1. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Annals of Internal Medicine 2007;146(2):77-86.
2. Bierer G, Balfe D, Wilcox WR, Mosenifar Z. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. Journal of Inherited Metabolic Disease 2006;29(4):572-9.
3. Bierer G, Wilcox WR, Balfe D, Mosenifar Z. Improvement in cardiopulmonary exercise testing during enzyme replacement therapy in Fabry disease [abstract]. Proceedings of the American Thoracic Society International Conference;2005 May 20-25; San Diego, California. 2005:A493. [CENTRAL: 593031; CRS: 5500100000002992;]
4. Clarke JT, West ML, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genetics in Medicine 2007;9(8):504-9. [CENTRAL: 701854; CRS: 5500050000000085; PUBMED: 17700388]
5. Desnick RJ, International FDSG. Enzyme therapy for Fabry disease [abstract]. Journal of Inherited Metabolic Disease 2001;24 Suppl:774. [CENTRAL: 593054; CRS: 5500100000003012;]
6. Desnick RJ, International Fabry Study Group. Fabry disease enzyme therapy: phase 3 and extension results [abstract]. Journal of Inherited Metabolic Disease 2001;24 Suppl 1:98.
7. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. New England Journal of Medicine 2001;345(1):9-16.
8. Lee P, Banikazemi M, Guffon N, Wilcox WR, Waldek S, Germain DP, et al. Severe glomerulosclerosis and proteinuria may influence response to therapy in fabry disease [abstract]. Journal of Inherited Metabolic Disease 2003;26 Suppl 2:158.
9. Linthorst GE, Aerts JMFG, Bosman DK, Heymans HSA, Hollack CEM. Aenzyme-supplementation therapy for Fabry disease: first possible treatment [abstract]. The Netherlands Journal of Medicine 2001;58:A22.
10. Thurberg BL, Byers RH, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. Journal of Investigative Dermatology 2004;122(4):900-8.
11. Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW. Cardiac Microvascular Pathology in Fabry Disease Evaluation of Endomyocardial Biopsies Before and After Enzyme Replacement Therapy. Circulation 2009;119(19):2561-7.
12. Thurberg BL, Phelps R, Granter S, Byers R, Gordon RE, O'Callaghan M. Fabrazyme clears globotriaosylceramide from the skin of fabry patients [abstract]. Journal of Inherited Metabolic Disease 2003;26 Suppl 2:174.
13. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney International 2002;62(6):1933-46.
14. Waldek S, Germain D P, Banikazemi M, Guffon N, Lee P, Linthorst G, et al. Stabilization of renal function after enzyme replacement therapy in Fabry Disease [abstract]. Nephrology Dialysis Transplantation 2003;18 Suppl 4:630.
15. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. American Journal of Human Genetics 2004;75(1):65-74.
16. HajioffD, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. Journal of Inherited Metabolic Disease 2003;26(8):787-94.
17. HajioffD, Goodwin S, Quiney R, Zuckerman J, MacDermot KD, Mehta A. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatrica 2003;92(443):28-30.
18. HajioffD, Quiney RE, Zuckerman J, McDermott K Mehta A. Hearing loss in Fabry's disease: the effect of alpha-galactosidase A replacement therapy [abstract]. Annals of Neurology 2003;54 Suppl 7:S26.
19. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94(2):153-8.
20. Hughes DA, Deegan PB, Milligan A, Wright N, Butler LH, Jacobs A, et al. A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease. Molecular Genetics and Metabolism 2013;109(3):269-75. [CENTRAL: 960223; CRS: 5500050000000134; EMBASE: 2014003031]
21. Brady RO, Murray GJ, Moore DF, Schiffmann R. Enzyme replacement therapy in Fabry disease. Journal of Inherited Metabolic Disease 2001;24 Suppl 2:18-24. [CENTRAL: 444520; CRS: 5500100000002339; PUBMED: 11758675]
22. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurology 2002;2:4.
23. Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33(2):525-31.
24. Moore DF, Scott LTC, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001;104(13):1506-12.
25. Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 2006;34(1):53-6.
26. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al. Clinical effect of enzyme replacement in Fabry disease [abstract]. Journal of Inherited Metabolic Disease 2001;24(7):775.
27. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285(21):2743-9.
28. Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K5, Doucette S, et al. Outcomes of patients treated through the Canadian Fabry disease initiative. Molecular Genetics and Metabolism 2014;111:499-506.
29. Sirrs SM, Bichet DG, Casey R, Clarke JTR, Flowerdew G, Lemoine K, et al. Agalsidase alfa and agalsidase beta have similar effects on fabry outcomes results from the Canadian fabry disease initiative [abstract]. Journal of Inherited Metabolic Disease 2010;33 Suppl 1:S126, Abstract no: 396-P. [CENTRAL: 1000726; CRS: 5500131000000068;]
30. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Online CONSORT checklist S1 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg' [online]. PLoS One 2007; Vol. 2, issue 7:e598.
31. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Online supporting information to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg' [online]. PLoS One 2007; Vol. 2, issue 7:e598.
32. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Online trial treatment protocol S1 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg' [online]. PLoS One 2007; Vol. 2, issue 7:e598.
33. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Online trial treatment protocol S2 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg' [online]. PLoS One 2007; Vol. 2, issue 7:e598.
34. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2007;2(7):e598.
35. Alamartine E. Enzyme replacement therapy in nine patients with Fabry disease. Medical Science 2005;21 Suppl 11:62-5.
36. Banikasemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Molecular Genetics and Metabolism 2005;85:255-59.
37. Beck M, Ricci R, Widmer U, Dehout F, Garcia AL, Kampmann C, et al. Fabry disease: overall effects of agalsidase alfa treatment. European Journal of Clinical Investigation 2004;34(12):838-44.
38. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. American Journal of Cardiology 2006;97(10):1515-8.
39. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney international 2006;69(7):1216-21.
40. Cartwright DJ, Cole AL, Cousins AJ, Lee PJ. Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy. Journal of Inherited Metabolic Disease 2004;27(6):791-93.
41. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006;92(3):357-60.
42. Eto Y, Ohashi T, Utsunomiya Y, Fujiwara M, Mizuno A, Inui K, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. Journal of Inherited Metabolic Disease 2005;28(4):575-83.
43. Tsuboi K. Evaluation of therapeutic efficacy in Fabry disease using Lyso-Gb3 as an indictor. Journal of inherited metabolic disease 2014;37(1):S154.
44. Fellgiebel A, Gartenschläger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovascular Diseases 2014;38(6):448-56. [CENTRAL: 1104089; CRS: 5500135000001422; PUBMED: 25502511]
45. FernhoffP, Goker-Alpan O, Holida M, Nedd K, Barshop BA, Mardach R, et al. Safety and tolerability of agalsidase alfa in patients with Fabry disease formerly treated with agalsidase beta. Journal of Inherited Metabolic Disease 2011;34 Suppl 3:S227.
46. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. Journal of the American Society of Nephrology 2007;18(5):1547-57.
47. Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry. Genet Med 2013;15(12):958-65.
48. Guffon N. The clinical benefit of Fabrazyme treatment [abstract]. Journal of Inherited Metabolic Disease 2002;25 Suppl 1:116.
49. Guffon N, Fouilhoux A. Clinical benefit in Fabry patients given enzyme replacement therapy - a case series. Journal of Inherited Metabolic Disease 2004;27(2):221-7.
50. HajioffD, Hegemannn S, Conti G, Beck M, Sunder-Plassmann G, Widmer U, et al. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. European Journal of Clinical Investigation 2006;36(9):663-7.
51. Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 2004;62(7):1066-72.
52. Jardim LB, Gomes I, Netto CB, Nora DB, Matte US, Pereira F, et al. Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease. Journal of Inherited Metabolic Disease 2006;29(5):653-9.
53. Jardim LB, Aesse F, Vedolin LM, Pitta-Pinheiro C, Marconato J, Burin MG, et al. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arquivos de Neuro-Psiquiatria 2006;64(3B):711-7.
54. Kalliokoshi RJ, Kantola I, Kalliokoshi KK, Engblom E, Sundell J, Hannujainen JC, et al. The effect os 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. Journal of Inherited Metabolic Disease 2006;29:112-8.
55. Kampmann C, Ries M, Bahner F, Kim KS, Bajbouj M, Beck M. Influence of enzyme replacement therapy (ERT) on Anderson Fabry disease associated hypertrophic infiltrative cardiomyopathy (HIC). European Journal of Pediatrics 2002;161(2):R5.
56. Kim CO, Oh ES, Park MS. First-in-human study with new recombinant agalsidase beta (ISU303) in healthy subjects. J Clin Pharmacol 2014;54(6):675-81.
57. Kobayashi M, Ida H, Ohashi T, Eto Y. Safety of enzyme replacement therapy among 20 Japanese patients with classical type of Fabry disease [abstract]. Journal of Inherited Metabolic Disease 2005;28 Suppl 1:166.
58. Kosch M, Koch H-G, Oliveira JP, Soares C, Bianco F, Breuning F, et al. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney International 2004;66(3):1279-82.
59. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney International 2004;66(4):1589-95.
60. Linthorst Ge, Vedder AC, Ormel EE, Johannes AMFG, Hollak CEM. Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. Nephrology, Dialysis, Transplantation 2006;21:355-360.
61. Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney International 2004;65(4):1381-85.
62. Mills K, Vellodi A, Morris P, Cooper D, Morris M, Young E, et al. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. European Journal of Pediatrics 2004;163:163.
63. Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C, et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. American Journal of Kidney Diseases 2005;46(1):120-7.
64. Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatrica 2007;96(1):122-7.
65. Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006;118(3):924-32.
66. Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 2012;7(10):e47805.
67. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle & Nerve 2003;28(6):703-10.
68. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrology, Dialysis, Transplantation 2006;21(2):345-54.
69. Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, et al. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genet Med 2013;15(12):983-9.
70. Schiffmann R, Pastores GM, Lien YH, Castaneda V, Chang P, Martin R, et al. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study. Orphanet J Rare Dis 2014;26(9):169.
71. Sirrs SM, Flowerdew G, Whyte J, Lemoine K, Bichet DG, Casey R, et al. Rate of decline of GFR in patients with fabry disease (FD): prospective natural history data from the Canadian fabry disease initiative (CFDI) [abstract]. Journal of Inherited Metabolic Disease 2011;34 Suppl 3:S186, Abstract no: P-325. [CENTRAL: 1000727; CRS: 5500131000000069;]
72. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clinical Genetics 2004;66:158-65.
73. Tsuboi K, Yamamoto H, Goto H, Somura F, Kurimoto Y. Evaluation of the efficacy of enzyme replacement therapy for cardiac hypertrophy in Fabry disease [abstract]. Journal of Inherited Metabolic Disease 2014;37 Suppl 1:S154, Abstract np: P-425. [CENTRAL: 1000866; CRS: 5500131000000101;]
74. Tsuboi K, Yamamoto H, Goto H, Somura F, Kurimoto Y. Evaluation of therapeutic efficacy in Fabry disease using Lyso-Gb3 as an indictor [abstract]. Journal of Inherited Metabolic Disease 2014;37 Suppl 1:S154, Abstract no: P-424. [CENTRAL: 1000865; CRS: 5500131000000100;]
75. Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 2013;24(1):137-48.
76. Utsumi K, Mitsuhashi F, Asahi K, Sakurazawa M, Arii K, Komaba Y, et al. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments. Clinica Chimica Acta 2005;360(1-2):103-7.
77. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108(11):1299-301.
78. Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol 2014;25(4):837-49.
79. West M, Bichet D, Casey R, Clarked J, Sirrs S, LeMoine K, et al. Agalsidase alfa and agalsidase beta have similar effects on outcomes in Fabry disease - results from the Canadian Fabry disease initiative. Molecular Genetics and Metabolism 2011;102:S3-S47.
80. Benjamin ER, Hamler R, Brignol N, Boyd R, Yu J, Bragat A, et al. Migalastat reduces plasma globotriaosylsphingosine (lyso-Gb3) in Fabry patients: results from the FACETS phase 3 study [abstract]. Journal of Inherited Metabolic Disease 2014;37 Suppl 1:S161, Abstract no: P-448. [CENTRAL: 1000862; CRS: 5500131000000097;]
81. Germain DP, Bichet DG, Giugliani R, Hughes D, Schiffmann R, Wilcox W, et al. Subjects treated with migalastat continue to demonstrate stable renal function and reduced left ventricular mass index over 3 years in a long-term extension study of Fabry disease [abstract]. Journal of Inherited Metabolic Disease 2015;38(1 Suppl):Abstract no: O-050. [CENTRAL: 1157466; CRS: 5500135000001544;]
82. Nicholls K, Castelli J, Winkler R, Sitaraman SA, Benjamin ER, Wu X, et al. Migalastat HCl, an investigational pharmacological chaperone therapy: screen results from FACETS, a phase 3 study in male and female fabry patients [abstract]. Journal of Inherited Metabolic Disease 2012;35(Suppl 1):S95: Abstract P-242. [CENTRAL: 1000728; CRS: 5500131000000070;]
83. Hughes D, Skuban N, Johnson F, Lazauskas R, Williams HN, Kirk J, et al. Development of a next-generation ERT, ATB100C, for fabry disease [abstract]. Journal of Inherited Metabolic Disease 2014;37 Suppl 1:S158, Abstract no: P-440. [CENTRAL: 1000863; CRS: 5500131000000098;]
84. NCT00701415. A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms (FIELD). https://clinicaltrials.gov/ct2/show/NCT00701415 (accessed 14 July 2016).
85. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet Journal of Rare Diseases 2013;8:47.
86. Wijburg FA, Benichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, et al. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PloS One 2015;10(5):e0124987. [CENTRAL: 1157465; CRS: 5500135000001543; PUBMED: 25955246]
87. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, OttenhoffR, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proceedings of the National Academy of Sciences of the United States of America 2008;105(8):2812-7.
88. Arends M, Hollak CE, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet Journal of Rare Diseses 2015;10:77.
89. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
90. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians. BMJ 2008;336:995-8.
91. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
92. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 20011.
93. Hollak CE, Linthorst GE. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?. Molecular Genetics and Metabolism 2009;96(1):1-3.
94. Jones AP. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clinical trials 2009;6:16-27.
95. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281(3):249-54.
96. Niemann M, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet 2014;7(1):8-16.
97. Riccio E, Capuano I, Visciano B, Marchetiello C, Petrillo F, Pisani A. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. G Ital Nefrol 2013;30(5):gin/30.5.5.
98. Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, et al. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. Journal of Clinical Pharmacology 2007;47(10):1222-30.
99. Smith HJ, Taylor R, Mitchell A. A comparison of four quality of life instruments in cardiac patients: SF-36, QLI, QLMI, and SEIQoL. Heart 2000;84(4):390-4.
100. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. American Journal of Human Genetics 2006;79(1):31-40.
101. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care. London: BMJ Publishing Group, 2001:189-208.
102. Tang JL, Liu JLY. Misleading funnel plot for detection of bias in meta-analysis. Journal of Clinical Epidemiology 2000;53(5):477-84.
103. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. Journal of Clinical Epidemiology 2000;53(2):207-16.
104. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genetics in Medicine 2007;9(1):34-45.
105. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Molecular Genetics and Metabolism 2008;93(2):112-28.
106. Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. Journal of Pediatrics 2008;152(4):563-70.
107. Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, et al. Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Paediatr Suppl 2005;94(447):51-4.
108. El Dib RP, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD006663.pub2]
109. El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD006663.pub3]